A natural compound called cordycepin from Cordyceps mushrooms significantly improved both type 2 diabetes and fatty liver disease in mice by changing their gut bacteria and activating a specific metabolic pathway. According to Gram Research analysis, cordycepin enriched beneficial Clostridia bacteria and increased a bile acid called CA7S, which triggered hormone release that improved blood sugar and fat control. While these results are promising, human studies are needed before cordycepin can be recommended as a treatment.
A new study shows that cordycepin, a natural compound found in Cordyceps mushrooms, may help people with both type 2 diabetes and fatty liver disease. Researchers gave this mushroom extract to mice with both conditions and found it reduced blood sugar problems, liver fat buildup, and inflammation. According to Gram Research analysis, the compound works by changing the bacteria in the gut and activating a special pathway that helps the body handle glucose and fat better. While these results are promising, human studies are still needed to confirm if cordycepin could become a dietary treatment option.
Key Statistics
A 2026 research article published in The Journal of Nutritional Biochemistry found that cordycepin, a compound from Cordyceps mushrooms, significantly reduced glucose intolerance, liver fat accumulation, liver injury, inflammation, and oxidative stress in mice with both type 2 diabetes and fatty liver disease.
According to the 2026 study, cordycepin worked by enriching Clostridia bacteria in the gut and specifically increasing a bile acid called cholic acid-7-sulfate (CA7S), which activated a pathway that improved glucose and lipid metabolism in diabetic mice with fatty liver disease.
The research demonstrated that cordycepin outperformed the whole Cordyceps militaris mushroom extract, suggesting that cordycepin is the primary active compound responsible for the metabolic improvements observed in the diabetic mice with fatty liver disease.
The Quick Take
- What they studied: Whether cordycepin, a natural compound from Cordyceps mushrooms, could help treat fatty liver disease in people who also have type 2 diabetes
- Who participated: Male laboratory mice that were given a high-sugar, high-fat diet and a chemical injection to create conditions similar to type 2 diabetes combined with fatty liver disease
- Key finding: Cordycepin significantly reduced blood sugar problems, liver fat, inflammation, and oxidative stress in diabetic mice with fatty liver disease, working better than the whole mushroom extract
- What it means for you: This research suggests cordycepin could potentially become a dietary supplement for people with both diabetes and fatty liver disease, though human studies are needed before it can be recommended as a treatment
The Research Details
Researchers created a mouse model of type 2 diabetes combined with fatty liver disease by feeding mice a high-fructose, high-fat diet and giving them a chemical injection. They then treated some mice with cordycepin (the pure compound) and others with Cordyceps militaris water extract (the whole mushroom preparation). The researchers measured multiple outcomes including blood sugar levels, liver fat content, liver damage markers, inflammation levels, and oxidative stress. They also analyzed the gut bacteria composition and bile acid metabolism using advanced laboratory techniques to understand how cordycepin works at a molecular level.
The study used multi-omics analysis, which means they looked at the problem from multiple angles simultaneously—examining genes, proteins, metabolites, and bacteria all together. This comprehensive approach helped them trace the exact pathway by which cordycepin produces its beneficial effects. They specifically tracked changes in gut bacteria species and measured specific bile acids (compounds that help digest fat) to understand the mechanism of action.
This research approach is important because it doesn’t just show that cordycepin works—it explains exactly how it works. By identifying the specific gut bacteria that increase and the specific bile acid pathway that gets activated, researchers can better predict whether this compound might work in humans and can potentially develop it into a targeted therapy. Understanding the mechanism also helps identify which patients might benefit most from this treatment.
This is a well-designed animal study published in a peer-reviewed journal (The Journal of Nutritional Biochemistry). The researchers used multiple complementary analytical techniques to confirm their findings from different angles. However, this is a mouse study, so results may not directly translate to humans. The study was conducted in a controlled laboratory setting, which is different from real-world conditions. Additionally, the sample size for the animal groups is not specified in the abstract, which makes it harder to assess statistical power.
What the Results Show
Cordycepin produced impressive improvements across multiple measures of metabolic health. It reduced glucose intolerance (meaning the mice’s bodies handled blood sugar better), improved dyslipidemia (abnormal blood fat levels), decreased hepatic steatosis (fat accumulation in the liver), reduced liver injury markers, lowered inflammatory response, and decreased oxidative stress. The pure cordycepin compound outperformed the whole Cordyceps militaris water extract, suggesting that cordycepin is the active ingredient responsible for the benefits.
The mechanism behind these improvements involves changes to the gut microbiota. Cordycepin significantly increased the abundance of Clostridia bacteria, a class of microorganisms that appear to play a protective role. Specifically, it enriched several beneficial bacterial genera including Acetatifactor, Anaerovorax, and Monoglobus. These bacterial changes were closely linked to improvements in bile acid metabolism, which is the process by which the body produces and uses compounds that help digest and absorb fats.
The research identified a specific bile acid called cholic acid-7-sulfate (CA7S) as a key player in cordycepin’s benefits. Cordycepin activated a liver pathway called PXR/Sult2a1 that specifically produces more CA7S. This bile acid then activated a receptor called TGR5, which triggered the release of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood sugar and fat metabolism. This represents a complete mechanistic pathway from cordycepin consumption to improved metabolic health.
The study revealed strong correlations between increased CA7S levels and specific Clostridia bacteria species, including Monoglobus, Lachnoclostridium, and Anaerovorax. This suggests that cordycepin may work partly by enriching these bacteria, which then support CA7S production. The integrated analysis showed that multiple biological systems work together—the compound changes gut bacteria, which affects bile acid production, which then improves hormone signaling and metabolic control. This multi-system improvement explains why cordycepin was effective at addressing multiple aspects of the disease simultaneously.
Previous research has shown that cordycepin has hypoglycemic (blood sugar-lowering) and hypolipidemic (blood fat-lowering) effects, but this is the first study to examine its effects specifically in the context of type 2 diabetes combined with fatty liver disease. The finding that cordycepin works through gut microbiota modification aligns with emerging research showing that the microbiome plays a crucial role in metabolic diseases. The identification of the PXR/Sult2a1/CA7S/GLP-1 pathway adds to growing evidence that bile acid metabolism is a key link between gut bacteria and metabolic health.
This study was conducted entirely in mice, so results may not directly apply to humans. Mice metabolize compounds differently than people do, and their disease processes may not perfectly mirror human disease. The study does not specify the sample size for each treatment group, making it impossible to assess whether the findings are statistically robust. The research was conducted in a controlled laboratory environment, which differs significantly from real-world conditions where diet, stress, and other factors vary. Additionally, the study only examined male mice, so it’s unclear whether results would be similar in females. Finally, this is a single study, so the findings need to be replicated by other research groups before strong conclusions can be drawn.
The Bottom Line
Based on this research, cordycepin cannot yet be recommended as a treatment for people with type 2 diabetes and fatty liver disease. The evidence is currently limited to animal studies. However, the findings are promising enough to warrant human clinical trials. People with these conditions should continue following their doctor’s current treatment recommendations while staying informed about future research developments. Confidence level: Low (animal study only).
This research is most relevant to people with type 2 diabetes who also have fatty liver disease (NAFLD), as this is the specific condition studied. It may also be of interest to people with either condition alone, since cordycepin showed benefits for both glucose control and liver health. Healthcare providers treating metabolic diseases should monitor this research as it develops. People interested in functional foods and natural compounds for health may find this interesting, though they should be cautious about using cordycepin supplements without medical guidance until human studies are completed.
In the mouse study, cordycepin produced measurable improvements in metabolic markers, but the timeline for these improvements is not specified in the abstract. If cordycepin eventually proves effective in humans, realistic expectations would likely involve gradual improvements over weeks to months, similar to other metabolic interventions. However, this timeline is speculative until human studies are conducted.
Frequently Asked Questions
Can cordycepin from Cordyceps mushrooms help treat fatty liver disease in people with diabetes?
A 2026 mouse study found cordycepin significantly improved both conditions by changing gut bacteria and activating a metabolic pathway. However, human studies are needed before it can be recommended as a treatment. Talk to your doctor before using cordycepin supplements.
How does cordycepin work to improve diabetes and fatty liver disease?
Cordycepin enriches beneficial gut bacteria called Clostridia, which increases production of a bile acid called CA7S. This bile acid activates a hormone called GLP-1 that helps regulate blood sugar and fat metabolism, improving both conditions.
Is cordycepin better than taking the whole Cordyceps mushroom extract?
The 2026 study found that pure cordycepin was more effective than the whole mushroom water extract, suggesting cordycepin is the active ingredient. However, this was only tested in mice, so human studies are needed to confirm this finding.
What is the connection between gut bacteria and fatty liver disease?
This research shows that specific gut bacteria (Clostridia) produce bile acids that activate hormones controlling blood sugar and fat metabolism. Changes in gut bacteria composition can therefore affect liver health and metabolic function.
When might cordycepin supplements become available as a treatment for diabetes and fatty liver disease?
This mouse study is promising, but human clinical trials are needed before cordycepin can be approved as a medical treatment. This process typically takes several years. Cordycepin supplements are currently available commercially, but their effectiveness in humans hasn’t been proven.
Want to Apply This Research?
- Users with type 2 diabetes and fatty liver disease could track fasting blood glucose levels, liver enzyme markers (ALT and AST from blood tests), and triglyceride levels weekly or monthly to monitor metabolic improvements if they begin using cordycepin supplements under medical supervision
- Users could set a daily reminder to take a cordycepin supplement at the same time each day, paired with logging their dietary intake to ensure they’re also maintaining a healthy diet low in high-fructose foods and saturated fats, since the study used cordycepin alongside dietary changes
- Establish a baseline of metabolic markers (blood glucose, liver enzymes, lipid panel) before starting cordycepin, then retest every 4-8 weeks to track changes over time. Users should also note subjective improvements in energy levels, digestion, and overall well-being
This research was conducted in mice and has not been tested in humans. Cordycepin should not be used as a replacement for prescribed diabetes or liver disease treatments without consulting your healthcare provider. If you have type 2 diabetes, fatty liver disease, or both, speak with your doctor before starting any new supplements, including cordycepin products. The findings from this animal study may not directly apply to humans. Always follow your doctor’s treatment recommendations and maintain regular medical monitoring.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.